The present invention relates to a eutectic formulation for rapid nose-to-brain transport upon intranasal administration and method of manufacturing the same. The formulation comprises triturates of micronized or crystalline zolmitriptan with nicotinamide, to form a eutectic. The formulation was characterized using differential scanning calorimetry, powder X-ray diffraction, and FTIR spectroscopy to confirm its eutectic nature and generated a phase diagram. Groups of rats received zolmitriptan intravenously or intranasally, or intranasal eutectic formulation. Pharmacokinetics in these tissues indicated the superiority of the intranasal eutectic formulation for brain targeting. The formulation could be used to treat acute migraine attack.
